Stock Scorecard
Stock Summary for 4D Molecular Therapeutics Inc (FDMT) - $4.50 as of 8/1/2025 3:45:50 PM EST
Total Score
9 out of 30
Safety Score
45 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for FDMT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for FDMT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for FDMT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for FDMT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for FDMT (45 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for FDMT
Financial Details for FDMT
Company Overview |
|
|---|---|
| Ticker | FDMT |
| Company Name | 4D Molecular Therapeutics Inc |
| Country | USA |
| Description | 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 8/7/2025 |
Stock Price History |
|
| Last Day Price | 4.50 |
| Price 4 Years Ago | 21.94 |
| Last Day Price Updated | 8/1/2025 3:45:50 PM EST |
| Last Day Volume | 31,315,129 |
| Average Daily Volume | 389,536 |
| 52-Week High | 17.41 |
| 52-Week Low | 2.23 |
| Last Price to 52 Week Low | 101.79% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 38.07 |
| Sector PE | 60.92 |
| 5-Year Average PE | -5.82 |
| Free Cash Flow Ratio | 1.56 |
| Industry Free Cash Flow Ratio | 18.42 |
| Sector Free Cash Flow Ratio | 30.33 |
| Current Ratio Most Recent Quarter | 12.36 |
| Total Cash Per Share | 2.88 |
| Book Value Per Share Most Recent Quarter | 10.14 |
| Price to Book Ratio | 0.44 |
| Industry Price to Book Ratio | 19.12 |
| Sector Price to Book Ratio | 31.01 |
| Price to Sales Ratio Twelve Trailing Months | 9,063.51 |
| Industry Price to Sales Ratio Twelve Trailing Months | 48.61 |
| Sector Price to Sales Ratio Twelve Trailing Months | 40.24 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 46,324,600 |
| Market Capitalization | 208,460,700 |
| Institutional Ownership | 96.28% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -59.53% |
| Reported EPS 12 Trailing Months | -3.18 |
| Reported EPS Past Year | -0.86 |
| Reported EPS Prior Year | -2.98 |
| Net Income Twelve Trailing Months | -176,439,000 |
| Net Income Past Year | -160,868,000 |
| Net Income Prior Year | -100,837,000 |
| Quarterly Revenue Growth YOY | -50.00% |
| 5-Year Revenue Growth | -64.94% |
| Operating Margin Twelve Trailing Months | -383,007.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 133,526,000 |
| Total Cash Past Year | 149,336,000 |
| Total Cash Prior Year | 249,108,000 |
| Net Cash Position Most Recent Quarter | 133,526,000 |
| Net Cash Position Past Year | 149,336,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 510,606,000 |
| Total Stockholder Equity Prior Year | 307,829,000 |
| Total Stockholder Equity Most Recent Quarter | 469,723,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -156,243,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.37 |
| Free Cash Flow Past Year | -138,371,000 |
| Free Cash Flow Prior Year | -78,563,000 |
Options |
|
| Put/Call Ratio | 0.11 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.13 |
| MACD Signal | 0.13 |
| 20-Day Bollinger Lower Band | 2.63 |
| 20-Day Bollinger Middle Band | 3.76 |
| 20-Day Bollinger Upper Band | 4.90 |
| Beta | 2.80 |
| RSI | 52.57 |
| 50-Day SMA | 6.51 |
| 150-Day SMA | 14.86 |
| 200-Day SMA | 14.89 |
System |
|
| Modified | 8/1/2025 11:45:18 PM EST |